Portopulmonary hypertension

Clinical and Investigative Medicine

Volumn 34, Issue 3, 2011, Pages

  Hopps, Eugenia ^a   Valenti, Amelia ^a   Caimi, Gregorio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PULMONARY HYPERTENSION; REVIEW;

HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION;

EID: 80051757990     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. GUT 2003; 52:1355-62.
2. Fallon MB. Portopulmonary hypertension: new clinical insights and more questions on pathogenesis. Hepatology 2003; 37:253-5.
3. Umeda N, Kamath PS. Hepatopulmonary syndrome and portopulmonary hypertension. Hepatol Res 2009; 39:1020-2.
4. Kawut SM, Krowka JR, Trotter JF, Roberts KE, Benza RL, Badesch DB, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48:196-203.
5. Wells JT, Runo JR, Lucey MR. Portopulmonary hypertension. Hepatology 2008; 48:13-5.
6. Rodriquez-Roisin R, Krowka MJ, Herve P, Fallon MB. ERS (European Respiratory Society) Task Force-PHD Scientiifc committee. Highlights of the ERS task force on pulmonaryhepatic vascular disorders. J Hepatol 2005; 42: 924-7.
7. Halank M, Ewert R, Seyfarth HJ, Hoefken G. Portopulmonary hypertension. J Gastroenterol 2006; 41:837-47.
8. Herve P, Le Pavec J, Sztrymf B, Decante B, Savale L, Stibon O. Pulmonary vascular abnormalities in cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21:141-59.
9. Nayak RP, Li D, Matuschak GM. Portopulmonary hypertension. Curr Gastroenterol Rep 2009; 11:56-63.
10. Keller S, Karaa A, Paxian M, Clemens MG, Zhang JX. Inhibition of endothelin-1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis. Shock 2006; 25:306-13.
11. Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel E. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2:1039-42.
12. Ohara N, Futagawa S, Watanabe S, Fukasawa M, Takamori S. Clinical investigation of endothelin-1 and nitric oxide in patients with portal hypertension focusing on plasma levels and immunohistological staining of liver tissues. Hepatol Res 2001; 21: 40-54.
13. Roberts KE, Fallon MB, Krowka MJ, Benza RL, Knowles JA, Badesch DB et al. Serotonin transporter polymorphism in patients with portopulmonary hypertension. Chest 2009; 135:1470-5.
14. Roberts, KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179:835-42.
15. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care 1999; 159:1925-32.
16. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461-8.
17. Pellicelli AM, Barbaro G, Puoti C, Guarascio P, Lusi EA, Bellis L et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology 2010 [epub ahead of print].
18. Yang YY, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001; 36: 181-6.
19. Sakuma M, Souma S, Kitamukai O, Demachi J, Takahashi T, Suzuki J, et al. Portopulmonary hypertension-hemodynamics, pulmonary angiography, and configuration of the heart. Circ J 2005; 69: 1386-93.
20. Pilatis ND, Jacobs LE, Rerkpattanapipat P, Kotler MN, Owen A, Manzarbeitia C et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl 2000; 6:85-91.
21. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A et al. Diagnosis of portopulmonary hypertension in candidates for liver transpantation: a prospective study. Hepatology 2003; 37:401-9.
22. Rodriquez-Roisin R, Krowka MJ, Herve P. Pulmonary-hepatic vascular disorders. Eur Respir J 2004; 24:861-80.
23. Morales-Blanhir J, Santos S, de Jover L, Sala E, Parè C, Roca J et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting longterm response top oral vasodilators in pulmonary hypertension. Respir Med 2004; 98:225-34.
24. Whittle BJ, Moncada S. Nitric oxide: the elusive mediator of the hyperdynamic circulation of cirrhosis? Hepatology 1992; 16:1089-92.
25. Findlay JF, Harrison BA, Plevak DJ, Krowka MJ. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl 1999; 5:381-7.
26. Bosch J, D'Amico G, Garcia-Pagan JC. Portal hypertension. In: Schiff ER, Dorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. 9th Ed Philadelphia. Lippincott Williams & Wilkins, 2003; 429-86.
27. Provencher S, Hervé P, Jais X, Lebrec D, Humbert M, Simonneau G et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130:120-6.
28. Ota K, Shilo H, Kokawa H, Hubara K, Kim T, Akiyoshi N et al. Effects of nidefipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol 1995; 10:198-204.
29. Navasa M, Bosch J, Reichen J, Bru C, Mastai R, Zysset T et al. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology 1988; 8:850-4.
30. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007; 28:203-18.
31. Hoeper MM, Seyfarth HJ, Hoefken G, Wirtz H, SpiekerkoetterE, Pletz MW et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Resp J 2007; 30: 1096-102.
32. Swanson KL, Krowka MJ. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleveland Clin J Med 2008; 75: 121-32.
33. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351:1655-65.
34. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28:563-7.
35. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervè P et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension:prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-8.
36. Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999; 5: 362-5.
37. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M et al. Safety and e'cacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 2008; 14:287-91.
38. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178:637-43.
39. Acosta F, Sansano T, Palenciano GC, Domenech P, Falcon L, Robles R et al. Portopulmonary hypertension and liver transplantation: hemodynamic consequences at reperfusion. Transplant Proceed 2005; 37: 3865-66.
40. Krowka MJ, Mandell MS, Ramsay MAE, Kawut SM, Fallon MB, Manzarbeitia C et al. Hepatopulmonary Syndrome and Portopulmonary Hypertension: A Report of the Multicenter Liver Transplant Database. Liver Transplant 2004; 10: 174-82.